QIAN XIAOZHANG,PETERSEN KAMILLE DUMONG,SEHESTED MAXWELL,LICHENSTEIN HENRI,JEFFERS MIKE,RITCHIE JAMES
申请号：
NZ59946406
公开号：
NZ599464A
申请日:
2006.02.03
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
599464 Disclosed is the use of a histone deacetylase inhibitor PXD101 (also known as belinostat or (2E)-N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide in the manufacture of a medicament for the treatment of cancer, wherein said treatment comprises treatment with: (i) said histone deacetylase inhibitor and (ii) carboplatin and paclitaxel.
